Cipher Pharmaceuticals Inc.
Informe acción TSX:CPH
Capitalización de mercado: CA$327.5m
Cipher Pharmaceuticals Crecimiento futuro
Future controles de criterios 2/6 Se prevé un crecimiento anual de los beneficios y los ingresos de Cipher Pharmaceuticals de 12.7% y 18.8% por año respectivamente. Se prevé que el BPA crezca en un 13.4% al año. Se espera que la rentabilidad financiera sea de 14.2% en 3 años.
Información clave
12.7%
Tasa de crecimiento de los beneficios
13.4%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Pharmaceuticals 54.3% Tasa de crecimiento de los ingresos 18.8% Rentabilidad financiera futura 14.2% Cobertura de analistas Low
Última actualización 08 Nov 2024
Actualizaciones recientes sobre el crecimiento futuro
Mostrar todas las actualizaciones
Cipher Pharmaceuticals' (TSE:CPH) Anemic Earnings Might Be Worse Than You Think Nov 14
Investor sentiment deteriorates as stock falls 15% Nov 14
With A 29% Price Drop For Cipher Pharmaceuticals Inc. (TSE:CPH) You'll Still Get What You Pay For Nov 12
Price target increased by 10% to CA$18.59 Nov 10
Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now Nov 09
Third quarter 2024 earnings: EPS misses analyst expectations Nov 09
Price target increased by 7.4% to CA$17.37 Nov 08
Cipher Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024 Nov 04
Cipher Pharmaceuticals Inc. Appoints Hamed Ghanei as Chief Business Officer Oct 08
Investor sentiment improves as stock rises 16% Oct 03
Investor sentiment deteriorates as stock falls 17% Sep 16
Investor sentiment improves as stock rises 19% Aug 19
Consensus EPS estimates increase by 10% Aug 15
Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 09 Cipher Pharmaceuticals Inc. Announces CFO Changes
Cipher Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 08, 2024 Aug 02
Consensus revenue estimates increase by 37% Jul 30
Investor sentiment improves as stock rises 16% Jul 30
First quarter 2024 earnings released: EPS: US$0.21 (vs US$0.10 in 1Q 2023) May 10
Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024 Apr 09
There's No Escaping Cipher Pharmaceuticals Inc.'s (TSE:CPH) Muted Earnings Despite A 26% Share Price Rise Mar 23
Weak Statutory Earnings May Not Tell The Whole Story For Cipher Pharmaceuticals (TSE:CPH) Mar 22
Investor sentiment improves as stock rises 27% Mar 21
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 15
Cipher Pharmaceuticals Inc. to Report Q4, 2023 Results on Mar 14, 2024 Mar 09
Investor sentiment improves as stock rises 16% Feb 05
Investor sentiment improves as stock rises 15% Jan 04
Consensus EPS estimates increase by 53% Nov 16
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 12
Cipher Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 09, 2023 Oct 28
Investor sentiment improves as stock rises 15% Sep 11 Cipher Pharmaceuticals Inc. (TSX:CPH) announces an Equity Buyback for CAD 6 million worth of its shares. Sep 06
Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 11
Cipher Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 10, 2023 Jul 29
Less than half of directors are independent Jun 03
Consensus EPS estimates increase by 17% Jun 02
Consensus revenue estimates decrease by 12% May 18
First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind May 12
Cipher Pharmaceuticals Inc. to Report Q1, 2023 Results on May 11, 2023 May 05
Interim CEO & Chairman of the Board exercised options to buy CA$411k worth of stock. Apr 11
Interim CEO & Chairman of the Board exercised options to buy CA$462k worth of stock. Apr 02
Full year 2022 earnings: EPS exceeds analyst expectations Mar 17
Cipher Pharmaceuticals Inc. Declares Quarterly Dividend, Payable on or About February 28, 2023 Feb 14
Independent Director recently sold CA$61k worth of stock Dec 15
Price target increased to CA$4.13 Nov 16
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 12
Cipher Pharmaceuticals Inc. to Report Q3, 2022 Results on Nov 10, 2022 Oct 27
Second quarter 2022 earnings released: EPS: US$0.08 (vs US$0.10 in 2Q 2021) Aug 12
Cipher Pharmaceuticals Inc. Announces Appointment of Bryan Jacobs as Chief Financial Officer Aug 12
Cipher Pharmaceuticals Inc. to Report Q2, 2022 Results on Aug 11, 2022 Aug 06
John Mull Decides Not to Stand for Re-Election as Director of Cipher Pharmaceuticals Inc Jun 23
Here's Why I Think Cipher Pharmaceuticals (TSE:CPH) Is An Interesting Stock May 14
First quarter 2022 earnings: EPS exceeds analyst expectations May 13 Cipher Pharmaceuticals Inc. to Report Q1, 2022 Results on May 12, 2022 May 10
Price target increased to CA$3.30 Apr 27
Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 22, 2022 Apr 19
Full year 2021 earnings: EPS exceeds analyst expectations Mar 19
Investor sentiment improved over the past week Feb 08
Investor sentiment improved over the past week Dec 25
Investor sentiment deteriorated over the past week Nov 30
Third quarter 2021 earnings released: EPS US$0.03 (vs US$0.059 in 3Q 2020) Nov 12
Investor sentiment improved over the past week Sep 08
Consensus EPS estimates increase to US$0.31 Aug 19
Second quarter 2021 earnings released: EPS US$0.11 (vs US$0.015 in 2Q 2020) Aug 14
Price target increased to CA$1.82 Aug 14
Investor sentiment improved over the past week Aug 13
Investor sentiment improved over the past week Jun 12
Consensus revenue estimates increase to US$21.5m May 20
Analysts Just Published A Bright New Outlook For Cipher Pharmaceuticals Inc.'s (TSE:CPH) May 18
First quarter 2021 earnings released: EPS US$0.05 (vs US$0.092 in 1Q 2020) May 16
Consensus EPS estimates fall to US$0.17 May 01
Investor sentiment improved over the past week Mar 25
Price target increased to CA$1.69 Mar 23
Cipher Pharmaceuticals Inc. Just Missed EPS By 37%: Here's What Analysts Think Will Happen Next Mar 20
Cipher Pharmaceuticals Inc. to Report Q4, 2020 Results on Mar 18, 2021 Mar 11
Industry Analysts Just Upgraded Their Cipher Pharmaceuticals Inc. (TSE:CPH) Revenue Forecasts By 12% Jan 26
Price target raised to CA$1.65 Jan 20
Cipher Pharmaceuticals Receives Arbitration Award on Trulance Jan 16
Investor sentiment improved over the past week Jan 08
New 90-day high: CA$1.15 Jan 08
Third quarter 2020 earnings released: EPS US$0.06 Nov 15
Revenue and earnings beat expectations Nov 15
New 90-day low: CA$0.93 Nov 11
Cipher Pharmaceuticals Inc. to Report Q3, 2020 Results on Nov 12, 2020 Nov 05
New 90-day low: CA$1.02 Oct 20
Cipher Pharmaceuticals Inc. Approves the Appointment of Cathy Steiner as Director Oct 10
New 90-day low: CA$1.09 Sep 24
New 90-day low - CA$1.13 Aug 28
Earnings released Aug 14
Previsiones de crecimiento de beneficios e ingresos TSX:CPH - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions) Fecha Ingresos Beneficios Flujo de caja libre Flujo de caja operativo Núm. de analistas medio 12/31/2026 55 25 N/A 35 2 12/31/2025 50 23 N/A 26 3 12/31/2024 34 14 N/A 18 3 9/30/2024 26 16 -67 13 N/A 6/30/2024 22 23 17 17 N/A 3/31/2024 22 23 14 14 N/A 12/31/2023 21 20 16 16 N/A 9/30/2023 21 32 15 15 N/A 6/30/2023 20 28 13 13 N/A 3/31/2023 20 27 13 13 N/A 12/31/2022 21 27 11 11 N/A 9/30/2022 22 10 15 15 N/A 6/30/2022 21 8 11 11 N/A 3/31/2022 22 9 11 11 N/A 12/31/2021 22 8 14 14 N/A 9/30/2021 22 5 14 14 N/A 6/30/2021 23 6 12 12 N/A 3/31/2021 21 3 11 11 N/A 12/31/2020 22 4 11 12 N/A 9/30/2020 21 7 7 7 N/A 6/30/2020 22 3 10 11 N/A 3/31/2020 23 4 11 12 N/A 12/31/2019 22 3 7 8 N/A 9/30/2019 23 -1 6 8 N/A 6/30/2019 22 2 4 6 N/A 3/31/2019 23 3 0 2 N/A 12/31/2018 23 1 1 8 N/A 9/30/2018 28 6 7 13 N/A 6/30/2018 34 9 N/A 18 N/A 3/31/2018 37 11 N/A 19 N/A 12/31/2017 40 11 N/A 13 N/A 9/30/2017 34 7 N/A 11 N/A 6/30/2017 32 5 N/A 9 N/A 3/31/2017 31 1 N/A 10 N/A 12/31/2016 30 4 N/A 11 N/A 9/30/2016 33 6 N/A 8 N/A 6/30/2016 34 2 N/A 7 N/A 3/31/2016 34 1 N/A 7 N/A 12/31/2015 34 2 N/A 8 N/A 9/30/2015 32 3 N/A 12 N/A 6/30/2015 30 13 N/A 16 N/A 3/31/2015 30 18 N/A 19 N/A 12/31/2014 29 19 N/A 25 N/A 9/30/2014 33 31 N/A 23 N/A 6/30/2014 32 27 N/A 18 N/A 3/31/2014 29 25 N/A 15 N/A 12/31/2013 25 24 N/A 7 N/A
Mostrar más
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (12.7% al año) de CPH es superior a la tasa de ahorro (2.3%).
Beneficios vs. Mercado: Se prevé que los beneficios (12.7% al año) de CPH crezcan menos que el mercado Canadian (16.5% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de CPH crezcan, pero no significativamente .
Ingresos vs. Mercado: Se prevé que los ingresos (18.8% al año) de CPH crezcan más rápidamente que los del mercado Canadian (7.1% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 18.8% al año) de CPH crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de CPH sea baja dentro de 3 años (14.2%).
Descubre empresas en crecimiento Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
